ACEA Biosciences Introduces the xCELLigence RTCA CardioECR System -, NewsCenter17, StormCenter17, Central Illinois News-

ACEA Biosciences Introduces the xCELLigence RTCA CardioECR System


This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.


First Platform with Simultaneous Measurement of Cardiomyocyte Contractility and Electrophysiology

San Diego, CA (PRWEB) September 04, 2014

In response to the need for more predictive preclinical assays for cardiac liability, ACEA Biosciences, Inc. has introduced its next generation Cardio System, the xCELLigence RTCA CardioECR System. Building on the success of the impedance-only RTCA Cardio System, the new RTCA CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function. RTCA CardioECR is the first platform to allow simultaneous cardiomyocyte contractility and field potential measurement. The system is designed to be placed in a standard tissue culture incubator with physiological temperature, CO2 level and humidity, allowing better controlled assays with both short-term and long-term measurements in real-time.

With the added MEA capabilities and pacing stimuli, the new CardioECR System allows for a deeper assessment of mechanism of toxicity. Field potential recording provided by MEA electrodes is a measure of the integrated ion channel activity that may be impacted by the tested compound, whereas the pacing function allows for controlling the rate of contractility for a more controlled assay. Furthermore, this combined dual readout system also provides a longer-term measurement of cardiomyocyte viability which can potentially identify those compounds causing longer-term structural damage to cardiomyocytes.

Cardiovascular toxicity is consistently a leading cause of drug attrition and withdrawal, noted Yama Abassi, Ph.D., Vice President of ACEA Biosciences, Inc. A number of drugs have been withdrawn from the market due to the risk of causing a potentially fatal form of ventricular arrhythmia referred to as Torsades de Pointes (TdP). The RTCA CardioECR system provides a higher throughput and more predictive approach that can be used earlier in drug development to reduce both cost and risk. We are confident this new system will provide significant benefit to the pharmaceutical industry and help support development of safer medicines for patients. We believe that it is also well aligned with the FDA CiPA initiative.

The Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative by the FDA seeks to develop a new paradigm for cardiac safety evaluation of new drugs that utilizes high throughput, predictive and mechanistic assays which can identify pro-arrhythmic compounds earlier in the drug discovery process. An important part of this initiative is to use cardiomyocyte model systems together with platforms that can provide incisive information on the pro-arrhythmic risk of compounds (Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N. Am Heart J. 2014 Mar;167(3):292-300.)

The xCELLigence RTCA CardioECR system will be on display at ACEAs 3rd xCELLigence Cardio Symposium: Advancements Cardiac Safety and Toxicology Research Focusing on the FDA CiPA Initiative in Arlington, VA on October 17-18, 2014, and the SPS Annual Meeting in Washington, DC on Oct 19-22, 2014.

For more information, please visit
Media Contact: Leslie Eisenberg | | O: 617.244.3872

For the original version on PRWeb visit:

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact

Powered by WorldNow

904 South Side Drive
Decatur, IL 62521
Primary Phone: 217-424-2500
Primary Email:

All content © Copyright 2000 - 2014, WorldNow and WAND. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms